These five miRNAs also work in combination to classify AD and MCI, and classification performance was further improved when the miRNAs were combined with CSF Aβ1–42 and tau ratio measurements27, demonstrating the potential of miRNAs to serve as longitudinal biomarkers for at least AD. The gene discussed is MAPT; the disease is Alzheimer disease.